Sinovac Biotech Ltd., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of vaccines against hepatitis A, hepatitis B, influenza viruses, and mumps in the People's Republic of China. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine; Split viron pandemic influenza vaccine; and RabEnd, an animal rabies vaccine. The company also develops the EV71 vaccine, which has completed Phase III clinical trial. In addition, it has completed pre-clinical studies for varicella, sabin inactivated polio, and hepatitis A and B vaccines; and focuses on commencing clinical trials for pneumococcal polysaccharide vaccine, pneumococcal conjugate vaccine, and rubella vaccine. The company has a collaboration agreement with Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and a license agreement with Medimmune, LLC to use patented reverse genetics technology pertaining to H5N1 influenza virus strain production for vaccines. Sinovac Biotech Ltd. was founded in 1999 and is headquartered in Beijing, the People's Republic of China.